IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

NCT06713837 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

339

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Relapse/Recurrence

Interventions

DRUG: High intensity therapies
DRUG: Low intensity therapies

Sponsor

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]